Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Longeveron announces abstract on data of Phase 1 trial of Lomecel-B infusion » 08:06
06/24/21
06/24
08:06
06/24/21
08:06
LGVN

Longeveron

$7.51 /

+0.14 (+1.90%)

Longeveron announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LGVN Longeveron
$7.51 /

+0.14 (+1.90%)

LGVN Longeveron
$7.51 /

+0.14 (+1.90%)

  • 12
    Feb
LGVN Longeveron
$7.51 /

+0.14 (+1.90%)

Over a week ago
Hot Stocks
Longeveron appoints Ursula Ungaro to board of directors » 09:05
05/25/21
05/25
09:05
05/25/21
09:05
LGVN

Longeveron

$6.07 /

-0.33 (-5.16%)

Longeveron announced that…

Longeveron announced that Ursula Ungaro will be joining its Board of Directors as of June 1, 2021. Ungaro was appointed to serve on the federal U.S. District Court for the Southern District of Florida in 1992 after being nominated by President George H.W. Bush and being confirmed by the U.S. Senate. After 29 years of federal service, Ms. Ungaro has announced that she will be retiring from the bench on May 31, 2021.

ShowHide Related Items >><<
LGVN Longeveron
$6.07 /

-0.33 (-5.16%)

LGVN Longeveron
$6.07 /

-0.33 (-5.16%)

  • 12
    Feb
LGVN Longeveron
$6.07 /

-0.33 (-5.16%)

Over a month ago
Hot Stocks
Longeveron names Dan Gincel SVP, strategic collaborations, scientific affairs » 09:08
05/18/21
05/18
09:08
05/18/21
09:08
LGVN

Longeveron

$5.26 /

-0.055 (-1.03%)

Longeveron announced the…

Longeveron announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs. Previously, he served as Vice President of University Partnerships and a member of the Executive Leadership Team at the Maryland Technology Development Corporation, where he oversaw programs to accelerate the commercialization of technologies from federal, state, and private Maryland research institutions.

ShowHide Related Items >><<
LGVN Longeveron
$5.26 /

-0.055 (-1.03%)

LGVN Longeveron
$5.26 /

-0.055 (-1.03%)

  • 12
    Feb
LGVN Longeveron
$5.26 /

-0.055 (-1.03%)

Hot Stocks
Longeveron expects cash to cover requirements through at least 4Q22 » 08:17
05/14/21
05/14
08:17
05/14/21
08:17
LGVN

Longeveron

$5.22 /

-0.04 (-0.76%)

Cash in the first quarter…

Cash in the first quarter of 2021 was increased by the $29.1 million in funds received from the IPO. As of March 31, 2021, the Company's cash position was $24.5 million. The Company believes, based on the current operating plan and financial resources, that existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.

ShowHide Related Items >><<
LGVN Longeveron
$5.22 /

-0.04 (-0.76%)

LGVN Longeveron
$5.22 /

-0.04 (-0.76%)

  • 12
    Feb
LGVN Longeveron
$5.22 /

-0.04 (-0.76%)

Earnings
Longeveron reports Q1 EPS (18c) vs. 0c last year » 08:16
05/14/21
05/14
08:16
05/14/21
08:16
LGVN

Longeveron

$5.22 /

-0.04 (-0.76%)

Reports Q1 revenue $0.4M…

Reports Q1 revenue $0.4M vs. $1.7M last year. "Aging is the number one risk factor for chronic disease," said Geoff Green, CEO. "Stem cell exhaustion, cellular senescence, and chronic inflammation, together referred to as "inflammaging", compromises our ability to repair and regenerate damaged tissues and organs. Inflammaging is linked to the rise of progressive chronic diseases such as Alzheimer's disease and Aging Frailty. Our focus since day one has been to develop safe and effective allogeneic cell therapy solutions for the treatment and prevention of these diseases."

ShowHide Related Items >><<
LGVN Longeveron
$5.22 /

-0.04 (-0.76%)

LGVN Longeveron
$5.22 /

-0.04 (-0.76%)

  • 12
    Feb
LGVN Longeveron
$5.22 /

-0.04 (-0.76%)

Hot Stocks
Longeveron announces completion of Phase I/II study of lomecel-b infusion » 08:44
04/15/21
04/15
08:44
04/15/21
08:44
LGVN

Longeveron

$7.51 /

+0.18 (+2.46%)

Longeveron announced the…

Longeveron announced the completion of the Company's Phase I/II clinical study of the use of Lomecel-B to improve immune response to influenza vaccine in subjects with Aging Frailty. Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell product manufactured under current good manufacturing practices by Longeveron. The two-phase, multicenter, randomized, double-blinded, placebo-controlled study was conducted at 7 hospitals and clinics throughout Florida and Maryland, and was supported in part by a grant from Maryland Stem Cell Research Fund under the Maryland Technology Development Corporation and the National Institute on Aging. It is well established that an aging immune system is less effective at producing protective antibodies following vaccination, and this reduced immune response contributes to the aging process in general. People with aging frailty are more prone to inflammaging and are more likely to have greater susceptibility to infectious diseases and reduced responses to vaccination. Although commercially available vaccines against influenza provide protection and likely lasting immunological memory in children and adults, they are much less effective in older and frail individuals. Lomecel-B has the potential to reduce inflammation associated with Aging Frailty, and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can balance the immune system and improve the function of B lymphocytes. As B cells are responsible for antibody production in response to vaccines, Lomecel-B may boost antibody generation and immunity following vaccination in subjects with Aging Frailty. It is anticipated that the top-line trial results will be announced in the 3rd quarter of 2021. In the open-label Phase I trial, elderly subjects considered to be mild-to-moderately frail per the Clinical Frailty Scale were randomized to receive a single peripheral intravenous infusion of Lomecel-B either one week or four weeks before administration of the flu vaccine to evaluate whether timing of administration of Lomecel-B relative to the vaccine resulted in a significant difference in immune response. Based on the phase 1 results, administration of Lomecel-B one week in advance of flu vaccination was selected for the Phase II randomized, placebo-controlled trial. In Phase II, a total of 39 subjects were enrolled and treated, with 20 receiving placebo and 19 receiving Lomecel-B. The primary objectives of the study were to assess safety, and efficacy of Lomecel-B to improve response to flu vaccine through measurement of serum antibodies. Additional efficacy measures include assessments of physical strength and endurance, quality-of-life and activities of daily living assessments, cognitive function, and blood-based biomarkers.

ShowHide Related Items >><<
LGVN Longeveron
$7.51 /

+0.18 (+2.46%)

LGVN Longeveron
$7.51 /

+0.18 (+2.46%)

  • 12
    Feb
LGVN Longeveron
$7.51 /

+0.18 (+2.46%)

Hot Stocks
Longeveron: Lomecel-B Phase 1 study met primary endpoint » 08:35
04/13/21
04/13
08:35
04/13/21
08:35
LGVN

Longeveron

$6.91 /

+0.14 (+2.07%)

Longeveron announced the…

Longeveron announced the final results of its Phase I clinical study evaluating the safety and efficacy of intravenous administration of Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell product, in subjects with mild Alzheimer's disease. Preliminary results were previously reported in the company's S-1/A Registration Statement as part of Longeveron's successful Initial Public Offering in the first quarter of 2021. The study met its primary safety endpoint, which paves the way for future trials in subjects with Alzheimer's disease. Importantly, several pre-specified secondary efficacy endpoints and biomarker results support potential benefit from Lomecel-B. The complete trial results are currently being prepared for publication in a peer-reviewed journal, and will be posted on the Company's website in the future. Longeveron also indicated they are on track to commence a Phase 2 study of Lomecel-B in Alzheimer's disease in the second half of 2021. The phase 1 trial, funded in part by an Alzheimer's Association Part the Cloud Challenge on Neuroinflammation grant, used a randomized, placebo-controlled double-blind design testing single i.v. infusion of Lomecel-B 20 million cells, Lomecel-B 100 million cells, or placebo. Subjects were followed for 52 weeks post-infusion. Key findings from new and previously disclosed data: Lomecel-B infusion was well-tolerated in this trial, with no treatment-related serious adverse events observed throughout the 1-year follow-up, including no indications of amyloid-related imaging abnormalities as assessed by magnetic resonance imaging.

ShowHide Related Items >><<
LGVN Longeveron
$6.91 /

+0.14 (+2.07%)

LGVN Longeveron
$6.91 /

+0.14 (+2.07%)

  • 12
    Feb
LGVN Longeveron
$6.91 /

+0.14 (+2.07%)

Hot Stocks
Longeveron expects cash to cover requirements through at least 4Q22 » 07:29
03/30/21
03/30
07:29
03/30/21
07:29
LGVN

Longeveron

$5.67 /

-0.235 (-3.98%)

Our cash in the first…

Our cash in the first quarter of 2021 was increased by the $29.1 million in funds received from our IPO. As of March 30, 2021, our cash position was $24.5 million. We believe, based on the current operating plan and financial resources, that our existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.

ShowHide Related Items >><<
LGVN Longeveron
$5.67 /

-0.235 (-3.98%)

LGVN Longeveron
$5.67 /

-0.235 (-3.98%)

  • 12
    Feb
LGVN Longeveron
$5.67 /

-0.235 (-3.98%)

Earnings
Longeveron reports Q4 revenue $1.2M vs. $1.8M last year » 07:28
03/30/21
03/30
07:28
03/30/21
07:28
LGVN

Longeveron

$5.67 /

-0.235 (-3.98%)

Reports Q4 net loss $1.4M…

Reports Q4 net loss $1.4M vs. $0.5M last year. "We are proud of the significant progress made throughout 2020 and into 2021, including our successful IPO in February, which has positioned Longeveron with a stronger balance sheet and the ability to continue to advance the diverse Lomecel-B pipeline of trials," stated Geoff Green, Chief Executive Officer of Longeveron. "The Company was founded with the goal of developing safe and effective "off-the-shelf" cell therapies that could be used to treat chronic aging-related disease, improve health span and potentially extend longevity. In 2020, in conjunction with our funding partner, the Alzheimer's Association, we completed a Phase 1 Alzheimer's disease trial. We are extremely pleased with the safety and preliminary efficacy results. We look forward to announcing the final results in the second quarter of 2021 and initiating the planned Phase 2 multidose trial later this year. Additionally, both of our US Aging Frailty Phase 2 trials will have top line efficacy data available in the 3rd quarter of 2021. This will be very exciting year for Longeveron, with several clinical trial and clinical data-driven catalysts on the near horizon."

ShowHide Related Items >><<
LGVN Longeveron
$5.67 /

-0.235 (-3.98%)

  • 12
    Feb
LGVN Longeveron
$5.67 /

-0.235 (-3.98%)

Over a quarter ago
Hot Stocks
Longeveron's Lomecel-B approved by FDA for compassionate use » 09:17
03/11/21
03/11
09:17
03/11/21
09:17
LGVN

Longeveron

$7.20 /

+0.34 (+4.96%)

Longeveron announced that…

Longeveron announced that the U.S. Food & Drug Administration has granted expanded access approval for the administration of Longeveron's investigational cell therapy Lomecel-B to a child with Hypoplastic Left Heart Syndrome. Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell product manufactured under cGMP in Longeveron's cell processing facility in Miami, Florida. Dr. Sunjay Kaushal, MD, PhD, Division Head Cardiovascular Thoracic Surgery at Ann & Robert H. Lurie Children's Hospital of Chicago will administer Lomecel-B during a reconstructive cardiac surgery procedure.

ShowHide Related Items >><<
LGVN Longeveron
$7.20 /

+0.34 (+4.96%)

  • 12
    Feb
LGVN Longeveron
$7.20 /

+0.34 (+4.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.